Karl Sterling Podcast

← Karl Sterling Podcast4 dagen geleden · 47 min

The Future of Longevity: Dr. Aubrey de Grey and Dr. Kelsey Moody

The Future of Longevity: Dr. Aubrey de Grey and Dr. Kelsey Moody4 dagen geleden47 min

<p>Karl welcomes back longevity researchers Aubrey de Grey (LEV Foundation) and Kelsey Moody (Ichor), who first appeared on the show about two years ago.</p><p><strong>LEV Foundation update:</strong> Aubrey says the longevity field is speeding up. LEV’s own work has stalled for now because its next large combination study, with thousands of mice, needs philanthropic money, and wealthy donors are being pulled toward AI safety and toward investing in longevity companies. The good news is that every new mouse result gives LEV more interventions to combine.</p><p><strong>Ichor’s work:</strong> Kelsey runs two preclinical sites (Lafayette and Syracuse) and has added a clinical-trials arm in Syracuse that focuses on age-related disease. Ichor tests aging therapies in the eye first. The eye is small, so the drug costs less to make, and it’s immune-privileged, but the targets are meant for use across the whole body later. Its portfolio company Lento Bio has a small molecule that breaks protein crosslinks in the lens. In animal and cadaver lenses it restored about 50% of the lens’s flexibility. Human trials of an eye drop to replace reading glasses are expected in the second half of 2027. Ichor is recruiting trial participants in Central New York.</p><p><strong>Crosslinking:</strong> Aubrey explains that there are “easy” crosslinks, which can be reversed, and “hard” ones, which the body can’t repair. Crosslinks contribute to wrinkles, stiff arteries and high blood pressure in older people, and possibly to problems in the brain. When he first published in 2002 he had one approach for each of seven types of damage. Now there are several for each, and the list of damage types hasn’t grown.</p><p><strong>Brain and neuroplasticity:</strong> Late-life loss of neuroplasticity may come from fewer synapses, slower myelin repair and senescent astrocytes. In MS, the cells that rebuild myelin still exist but stop working as well, and the task is to restart them. In Parkinson’s, making dopamine is toxic to the neurons that produce it. Fetal cell transplants about 35 years ago sometimes left patients symptom-free for more than a decade. About five stem-cell trials are now underway. Aubrey couldn’t comment on DC electrical stimulation such as NEUBIE.</p><p><strong>Lifestyle:</strong> A sensible lifestyle matters, but going beyond it adds little, because breathing oxygen itself drives the damage. Stress matters, mainly in how you react to it. The real fix is repairing damage, like